ABSTRACT
In the review the current state of nutrition for patients with cancers is given. The role of nutrition in cancer etiology and prevention of cancers are discussed. Main principles of diet constriction in cancers are expounded.
Subject(s)
Diet , Diet/methods , Humans , Neoplasms/diet therapy , Neoplasms/etiology , Neoplasms/prevention & controlABSTRACT
The data on monoclonal antibody monotherapy (mabtera, rituximab) in 44 patients with B-cell low grade non-Hodgkin's lymphoma were assessed. Thirty-four of them had received several courses of second- or third line chemotherapy: mabtera was used as first-line therapy in 10. Mabtera was administered in a dose of 375 mg/m2 body surface, once a week, by slow intravenous infusion, 4-14 times depending on effect. Each relapsing patient received, on the average, 4 infusions, while each refractory one--8 weekly infusions. Overall response in the first group was 44%. Median overall relapse-free survival was 9 months. Apparenti effect of treatment was reported in 50% of primary patients (median overall relapse-free survival--15 months). Therapy was well tolerated. Fever and shivering stage I and II were among the most frequent post-infusion effects. High level of CD-20+B-lymphocytes should be used as prognostic indicator for effectiveness of therapy.
Subject(s)
Antibodies, Monoclonal/therapeutic use , Lymphoma, B-Cell/therapy , Lymphoma, Non-Hodgkin/therapy , Adult , Aged , Aged, 80 and over , Disease-Free Survival , Dose-Response Relationship, Immunologic , Humans , Middle Aged , RecurrenceABSTRACT
The paper presents the results of a complex investigation of patients with locally-advanced breast cancer who received neoadjuvant chemotherapy or chemoradiation at initial stage. The clinical and pathomorphological effects, nature of neoadjuvant therapy and number of courses were followed up for 5- and 10-year periods. A direct correlation was found between number of courses for chemotherapy-sensitive patients, on the one hand, and greater effect, more intensive medicinal pathomorphism and longer recurrence-free survival, particularly, at later stages, on the other.
Subject(s)
Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Breast Neoplasms/drug therapy , Neoadjuvant Therapy , Breast/pathology , Breast Neoplasms/mortality , Breast Neoplasms/pathology , Disease-Free Survival , Female , Follow-Up Studies , Humans , Time FactorsABSTRACT
A relationship between the dynamics of growth and pathological response of tumor cells and the number of neoadjuvant chemotherapy courses was established. As a result, there was no correlation between increase in overall and disease-free survival, on the one hand, and stage, on the other. An interval between neoadjuvant chemotherapy and surgery longer than 4 weeks had a negative effect on overall tumor response and duration of disease-free period.
Subject(s)
Antineoplastic Combined Chemotherapy Protocols/administration & dosage , Breast Neoplasms/pathology , Breast Neoplasms/therapy , Adult , Aged , Breast Neoplasms/drug therapy , Breast Neoplasms/mortality , Breast Neoplasms/surgery , Chemotherapy, Adjuvant , Combined Modality Therapy , Disease-Free Survival , Female , Humans , Middle Aged , Neoadjuvant Therapy , Neoplasm Staging , Predictive Value of Tests , Prognosis , Risk Factors , Survival Analysis , Time Factors , Treatment OutcomeABSTRACT
336 patients with locally-advanced breast cancer underwent neoadjuvant chemotherapy or chemoradiotherapy. Increase in T- and N-indices (change of stage after neoadjuvant chemotherapy) proved an important prognostic factor. Survival rates correlated with clinical effect and dropped as it diminished. This tendency was clear in both groups. There was no relationship between stage and overall and disease-free survival rates at early stages but later they declined as T- and N-indices decreased.
Subject(s)
Antineoplastic Combined Chemotherapy Protocols/administration & dosage , Breast Neoplasms/drug therapy , Breast Neoplasms/radiotherapy , Adult , Aged , Breast Neoplasms/mortality , Breast Neoplasms/pathology , Breast Neoplasms/surgery , Chemotherapy, Adjuvant , Disease-Free Survival , Female , Humans , Middle Aged , Neoadjuvant Therapy , Neoplasm Staging , Prognosis , Radiotherapy, Adjuvant , Remission Induction , Survival Analysis , Treatment OutcomeABSTRACT
A correlation was established between the end-results of neoadjuvant chemotherapy for locally-advanced breast cancer and pathological response of tumor cells. Also, the end-results correlated with CR or PR and pathological response. Only a small proportion of patients with tumor progression were registered as stage III or IV of pathological response (0.6 and 0.8%, respectively).
Subject(s)
Antineoplastic Combined Chemotherapy Protocols/administration & dosage , Breast Neoplasms/pathology , Breast Neoplasms/therapy , Adult , Aged , Breast Neoplasms/mortality , Chemotherapy, Adjuvant , Female , Humans , Middle Aged , Neoadjuvant Therapy , Neoplasm Staging , Survival Analysis , Treatment OutcomeSubject(s)
Breast Neoplasms/drug therapy , Etoposide/administration & dosage , Etoposide/toxicity , Administration, Oral , Adult , Aged , Antineoplastic Combined Chemotherapy Protocols/administration & dosage , Cyclophosphamide/administration & dosage , Epirubicin/administration & dosage , Female , Humans , Injections, Intravenous , Lymphatic Metastasis , Middle Aged , Neoplasm Metastasis , Time FactorsSubject(s)
Antiemetics/therapeutic use , Indoles/therapeutic use , Nausea/prevention & control , Serotonin Antagonists/therapeutic use , Vomiting/prevention & control , Adult , Aged , Antineoplastic Agents/adverse effects , Female , Humans , Male , Middle Aged , Nausea/chemically induced , Neoplasms/drug therapy , Treatment Outcome , Tropisetron , Vomiting/chemically inducedSubject(s)
Antineoplastic Agents/therapeutic use , Breast Neoplasms/drug therapy , Breast/diagnostic imaging , Breast Neoplasms/blood supply , Breast Neoplasms/diagnostic imaging , Chemotherapy, Adjuvant , Female , Humans , Microspheres , Sodium Pertechnetate Tc 99m , Technetium Tc 99m Aggregated Albumin , Tomography, Emission-Computed/methodsABSTRACT
Thirty seven patients received different modalities of chemotherapy for breast cancer disseminated to the liver. Apparent effect was registered in 9 (24.3%) patients (full effect--3 (8.1%), stabilization--23 (62.1%) and tumor progression--5 (13.5%). The ECE modality proved the most effective. Treatment efficacy was relatively higher in cases of breast tumor removal. The study established a correlation between effectiveness of therapy and size and number of metastatic nodes.
Subject(s)
Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Breast Neoplasms/pathology , Liver Neoplasms/diagnosis , Liver Neoplasms/drug therapy , Adult , Aged , Female , Humans , Liver Neoplasms/secondary , Middle Aged , Quality of Life , Single-Blind Method , Treatment OutcomeABSTRACT
A procedure for obtaining microcirculation coefficient is described. It is based on the phenomenon of formation of a focus of radionuclide hyperfixation on scintigrams of tumor area due to embolization of its arterioles and precapillaries with radionuclide. The method was used in 26 breast cancer patients before neoadjuvant chemotherapy. A direct correlation between the microcirculation coefficient and degree of tumor-induced pathomorphosis of tumor cells was established. The coefficient values proved more or less predictive of tumor response to chemotherapy.
Subject(s)
Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Breast Neoplasms/blood supply , Breast Neoplasms/drug therapy , Adult , Breast Neoplasms/diagnostic imaging , Chemotherapy, Adjuvant , Cyclophosphamide/administration & dosage , Doxorubicin/administration & dosage , Drug Evaluation , Embolization, Therapeutic , Female , Fluorouracil/administration & dosage , Humans , Microcirculation/diagnostic imaging , Middle Aged , Prognosis , Radionuclide Imaging , Sodium Pertechnetate Tc 99m , Time FactorsSubject(s)
Antineoplastic Agents/therapeutic use , Breast Neoplasms , Lung Neoplasms/drug therapy , Cyclophosphamide/therapeutic use , Doxorubicin/therapeutic use , Female , Fluorouracil/therapeutic use , Humans , Lung Neoplasms/secondary , Lymphatic Metastasis , Methotrexate/therapeutic use , Vincristine/therapeutic useSubject(s)
Aminoglutethimide/therapeutic use , Antineoplastic Agents/therapeutic use , Breast Neoplasms/drug therapy , Estrogen Antagonists/therapeutic use , Medroxyprogesterone/analogs & derivatives , Delayed-Action Preparations , Female , Humans , Medroxyprogesterone/therapeutic use , Medroxyprogesterone Acetate , Menopause , Middle Aged , Neoplasm Metastasis , Tamoxifen/therapeutic useSubject(s)
Adenocarcinoma/drug therapy , Antineoplastic Agents/therapeutic use , Estrogen Antagonists/therapeutic use , Progestins/therapeutic use , Uterine Neoplasms/drug therapy , 17 alpha-Hydroxyprogesterone Caproate , Adenocarcinoma/radiotherapy , Adult , Aged , Antineoplastic Agents/administration & dosage , Combined Modality Therapy , Drug Therapy, Combination , Estrogen Antagonists/administration & dosage , Female , Humans , Hydroxyprogesterones/administration & dosage , Hydroxyprogesterones/therapeutic use , Medroxyprogesterone/administration & dosage , Medroxyprogesterone/analogs & derivatives , Medroxyprogesterone/therapeutic use , Medroxyprogesterone Acetate , Middle Aged , Progestins/administration & dosage , Uterine Neoplasms/radiotherapySubject(s)
Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Breast Neoplasms/surgery , Mastectomy, Radical , Adult , Aged , Axilla , Cyclophosphamide/administration & dosage , Female , Fluorouracil/administration & dosage , Humans , Lymphatic Irradiation , Methotrexate/administration & dosage , Middle Aged , Preoperative Care , Vincristine/administration & dosageSubject(s)
Acyclovir/therapeutic use , Breast Neoplasms/drug therapy , Hodgkin Disease/drug therapy , Lymphoma, Non-Hodgkin/drug therapy , Adult , Aged , Breast Neoplasms/complications , Drug Evaluation , Herpesviridae Infections/drug therapy , Herpesviridae Infections/etiology , Hodgkin Disease/complications , Humans , Lymphoma, Non-Hodgkin/complications , Middle AgedABSTRACT
A total of 119 patients were treated for disseminated cancer of the mammary gland according to two schemes with the use of adriablastin. It was shown that in the treatment of metastases into the bones adriablastin was the drug of choice. The treatment of such patients with it may be effective. The analgetic action of the drug was noted in 80 per cent of the patients. The roentgenologically observed objective effect of the drug was provided by the doses higher than 300 mg and the treatment period of not less than 4 months. In the treatment of patients with metastases of other localization the schemes with the use of adriablastin had no advantage over the Cooper scheme.